Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipelin... Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2002 | -8.81938325991 | 2.27 | 2.86 | 1.93 | 2936961 | 2.4523436 | CS |
4 | 0.1398 | 7.24352331606 | 1.93 | 9.79 | 1.61 | 21638637 | 5.72759797 | CS |
12 | -1.2802 | -38.2149253731 | 3.35 | 9.79 | 1.53 | 7185871 | 5.53820162 | CS |
26 | -1.3802 | -40.0057971014 | 3.45 | 9.79 | 1.53 | 3137658 | 5.51254331 | CS |
52 | -3.3302 | -61.6703703704 | 5.4 | 10.35 | 1.53 | 1699494 | 5.65044701 | CS |
156 | -83.4662 | -97.5802001496 | 85.536 | 261.36 | 1.53 | 1085881 | 65.69570615 | CS |
260 | -947.2502 | -99.7819702524 | 949.32 | 1171.8 | 1.53 | 943110 | 131.76494291 | CS |
Symbole | Prix | Vol. |
---|---|---|
TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,72M |
NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,54M |
RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,75M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,29M |
CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,8M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales